Skip to content
10-K

Annual Report

Xilio Therapeutics, Inc. XLO

0001193125-26-118550

← back to feed
Filed
Mar 23, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 18, 2026 5.78M sh
Capex FY 2025 · Dec 31, 2025 $518K
Capex FY 2025 · Dec 31, 2024 $36K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$4.99M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$18.38M
Cash And Equivalents FY 2025 · Dec 31, 2025 $137.53M
Cash And Equivalents FY 2025 · Dec 31, 2024 $55.29M
Stockholders Equity FY 2025 · Dec 31, 2025 $35.27M
Stockholders Equity FY 2025 · Dec 31, 2024 $17.6M
Stockholders Equity FY 2025 · Dec 31, 2023 $36.83M
Current Liabilities FY 2025 · Dec 31, 2025 $56.27M
Current Liabilities FY 2025 · Dec 31, 2024 $27.26M
Total Liabilities FY 2025 · Dec 31, 2025 $119.41M
Total Liabilities FY 2025 · Dec 31, 2024 $53.48M
Current Assets FY 2025 · Dec 31, 2025 $145.03M
Current Assets FY 2025 · Dec 31, 2024 $60.23M
Total Assets FY 2025 · Dec 31, 2025 $154.69M
Total Assets FY 2025 · Dec 31, 2024 $71.08M
Eps Diluted FY 2025 · Dec 31, 2025 −$4.19
Eps Diluted restated FY 2025 · Dec 31, 2024 −$15.24
Eps Basic FY 2025 · Dec 31, 2025 −$4.19
Eps Basic restated FY 2025 · Dec 31, 2024 −$15.24
Sga Expense FY 2025 · Dec 31, 2025 $29.71M
Sga Expense FY 2025 · Dec 31, 2024 $24.78M
Rd Expense FY 2025 · Dec 31, 2025 $56.04M
Rd Expense FY 2025 · Dec 31, 2024 $41.21M
Net Income FY 2025 · Dec 31, 2025 −$35.04M
Net Income FY 2025 · Dec 31, 2024 −$58.24M
Operating Income FY 2025 · Dec 31, 2025 −$41.98M
Operating Income FY 2025 · Dec 31, 2024 −$60.58M
Revenue FY 2025 · Dec 31, 2025 $43.77M
Revenue FY 2025 · Dec 31, 2024 $6.34M